Stock Connect
Total 0 articles
Stock Connect
2026-08-03
38
美联储9月降息预期升至85%:全球热钱重估港股配置性价比,高股息与AI成长双线突围
随着美国7月非农数据走弱,美联储9月降息预期攀升至85%。降息周期开启叠加港股处于全球估值洼地,南向资金与外资形成共振。本文深度解析为何在当前宏观节点配置港股,探讨高股息防御与AI成长进攻的双线策略。
Read the full text
Stock Connect
2026-08-02
32
全球资金加速流向港股“避风港”:估值洼地叠加南向资金创年内新高,配置逻辑再强化
2026年8月初,全球资本市场面临美联储政策摇摆与地缘政治的双重压力,港股凭借其历史低位的估值、超5%的高股息率以及南向资金创纪录的净流入,正成为全球资金的“避风港”。本文深度解析当前港股配置的核心逻辑,揭示其与A股互补及国际化优势。
Read the full text
Stock Connect
2026-07-31
37
港股通标的年内第三次扩容,科技消费龙头纳入,配置窗口再开启
2026年7月31日,港股通标的名单年内第三次扩容,新纳入多只科技与消费龙头。本文解读扩容详情及对内地投资者的意义,分析港股配置价值与策略。
Read the full text
Stock Connect
2026-07-30
38
全球资管巨头贝莱德力挺港股:低估值高股息成配置优选
2026年7月30日,贝莱德发布报告称港股估值处于历史底部,恒生指数市盈率不足9倍,股息率超4%,建议全球投资者增配。本文从低估值、高分红、互联互通等角度解析港股配置价值,并提示汇率与地缘风险。
Read the full text
Stock Connect
2026-07-29
45
港交所再推改革:简化第二上市门槛,中概股回归浪潮下港股配置价值凸显
港交所于2026年7月28日宣布简化第二上市规则,降低市值及行业准入要求,此举将加速中概股回流。本文深入解读改革细节,分析其对港股市场结构、估值及资金流动的影响,并探讨当前为何是配置港股的关键窗口期。
Read the full textRelated tags
bg-secondary>Risk Warning
bg-secondary>Trading Rules
bg-secondary>HK Stock Account Opening
bg-secondary>Shenzhen-HK Stock Connect
bg-secondary>Shanghai-Hong Kong Stock Connect
bg-secondary>Pre-market and After-hours
bg-secondary>Fundamental Analysis
bg-secondary>Technical Analysis
bg-secondary>ETF Investing
bg-secondary>Red chip stocks
bg-secondary>China Enterprises Index
bg-secondary>Hang Seng Index
bg-secondary>IPO Gray Market
bg-secondary>Property Stocks
bg-secondary>Financial stocks
HK Stock Flash Quotes
1
Hong Kong ETF Trading Continues to Heat Up: Capturing Capital Flow Signals from Quoted Premiums and Discounts—Now Is the Time for Index Investing
2
What's the Difference Between the Hang Seng China Enterprises Index and the Hang Seng Index? Decoding the Capital Flow Signals Behind Hong Kong's Dual Index Quotes
3
How to Read Hong Kong Stock Quotes? Pre-Market, After-Hours and Closing Auction Explained — Mastering Real-Time Market Data
4
Hong Kong Stocks Enter Q3 Earnings Season: Read the Tape Signals and Capture New Blue-Chip Rotation Opportunities
5
Hong Kong Pharmaceutical Stock Market Analysis: Accelerating Drug Export, Valuation Recovery in Progress

